Evidence map›Paper›PMID 24136589›Full record

ArticleJournal of inherited metabolic disease2014

Non-specific accumulation of glycosphingolipids in GNE myopathy.

Katherine A Patzel, Tal Yardeni, Erell Le Poëc-Celic, Petcharat Leoyklang, Heidi Dorward, Dominic S Alonzi, Nikolay V Kukushkin, Bixue Xu, Yongmin Zhang, Matthieu Sollogoub and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. CDG Therapies: From Bench to Bedside.International journal of molecular sciences · 2018
    Review
  7. Identification of anMolecular genetics & genomic medicine · 2017
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 4 countries.

Katherine A PatzelOxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Tal Yardeni
Erell Le Poëc-Celic
Petcharat Leoyklang
Heidi Dorward
Dominic S Alonzi
Nikolay V Kukushkin
Bixue Xu
Yongmin Zhang
Matthieu Sollogoub
Yves Blériot
William A Gahl
Marjan Huizing
Terry D Butters
University of Oxford · GBInstitut Parisien de Chimie Moléculaire · FRNational Human Genome Research Institute · USNational Institutes of Health · USCentre National de la Recherche Scientifique · FRInstitut National des Sciences Appliquées de Toulouse · FRTel Aviv University · IL

Funding

Human Biochemical GeneticsZIAHG000215 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI GAHL, WILLIAM · 2009 to 2025
$72.6M
Cell Biology of Metabolic DisordersZIAHG200322 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI GAHL, WILLIAM · 2009 to 2014
$3.1M
Intramural NIH HHS ZIA HG200322
6 · The paper itself

Abstract

backgroundUDP-GlcNAc 2-epimerase/ManNAc 6-kinase (GNE) is a bifunctional enzyme responsible for the first committed steps in the synthesis of sialic acid, a common terminal monosaccharide in both protein and lipid glycosylation. GNE mutations are responsible for a rare autosomal recessive neuromuscular disorder, GNE myopathy (also called hereditary inclusion body myopathy). The connection between the impairment of sialic acid synthesis and muscle pathology in GNE myopathy remains poorly understood.

methodsGlycosphingolipid (GSL) analysis was performed by HPLC in multiple models of GNE myopathy, including patients' fibroblasts and plasma, control fibroblasts with inhibited GNE epimerase activity through a novel imino sugar, and tissues of Gne(M712T/M712T) knock-in mice.

resultsNot only neutral GSLs, but also sialylated GSLs, were significantly increased compared to controls in all tested models of GNE myopathy. Treatment of GNE myopathy fibroblasts with N-acetylmannosamine (ManNAc), a sialic acid precursor downstream of GNE epimerase activity, ameliorated the increased total GSL concentrations.

conclusionGNE myopathy models have increased total GSL concentrations. ManNAc supplementation results in decrease of GSL levels, linking abnormal increase of total GSLs in GNE myopathy to defects in the sialic acid biosynthetic pathway. These data advocate for further exploring GSL concentrations as an informative biomarker, not only for GNE myopathy, but also for other disorders of sialic acid metabolism.

Indexed as

AnimalsCase-Control StudiesCells, CulturedFemaleFibroblastsGlycosphingolipidsHexosaminesHumansMiceMice, Inbred C57BLMultienzyme ComplexesMusclesMuscular DiseasesMutationN-Acetylneuraminic AcidGlycosphingolipidsHexosaminesMultienzyme ComplexesN-acetylmannosamineN-Acetylneuraminic AcidUDP-N-acetylglucosamine 2-epimerase - N-acetylmannosamine kinase

Identifiers

PMID24136589
PMCPMC3979983
OpenAlexW2046051811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.